We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




CT Angiography Best for Emergency Diagnosis of Heart Disease in Low-Risk Patients

By HospiMedica International staff writers
Posted on 09 Aug 2012
Integrating coronary computed tomography angiography (CCTA) into the initial evaluation of low-risk patients arriving at hospital emergency departments (EDs) with chest pain reduces the time patients spend in the hospital without incurring additional costs or exposing patients to substantial risks. More...


The report of a study conducted at nine US hospitals was published July 26, 2012, in the New England Journal of Medicine (NEJM). “We found that the use of CCTA in emergency department evaluation of acute chest pain very effectively identified which patients did or did not have coronary artery obstruction, allowing clinicians to focus the use of resources on patients with heart disease,” said Udo Hoffmann, MD, MPH, director of the cardiac magnetic resonance (MR) positron emission tomography (PET) CT program at Massachusetts General Hospital (MGH; Boston, MA, USA) and corresponding author of the article. “Although the use of CCTA added to the amount of diagnostic testing used in the evaluation process, compared with current standard protocols it substantially reduced length of stay without increasing costs.”

CCTA combines sophisticated CT scanning with the use of intravenous contrast agents to generate detailed images of blood vessels supplying the heart without the need for cardiac catheterization. Several previous studies, including an immediate predecessor to the current one, have indicated that CCTA can effectively differentiate chest pain patients that do not have coronary artery disease, but those studies all had such limitations as lack of a control group or limited examination of factors such as costs and radiation exposure. The current study--ROMICAT (Rule Out Myocardial Infarction/Ischemia Using Computer Assisted Tomography)-II--was designed to determine whether a CCTA-based evaluation approach could improve clinical decision making at different hospitals across the country.

From April 2010 to January 2012, patients arriving at the participating hospitals’ EDs for evaluation of chest pain who had no history of cardiovascular disease and whose initial tests-- ECG and measurement of the biomarker troponin--did not clearly indicate a heart attack were invited to participate in the trial. Those who agreed to participate were randomly assigned to one of two groups. The control group proceeded with standard evaluation, with all diagnostic and treatment decisions being made by hospital physicians not part of the study group. The other group had CCTA as part of their ED evaluation, with the results being shared with attending physicians who, again, made all clinical decisions.

Participants who were discharged from the hospital within 24 hours of arrival were called within 72 hours to assess their status, and all participants were called 28 days after hospital discharge and asked whether any return ED visits or rehospitalizations had taken place. Participant responses were verified by checking their medical records. About 1,000 patients completed the study, including the 28-day follow-up.

The investigators found that participants in the CCTA group had significant reductions in the amount of time from ED arrival until discharge either from the ED or after a hospital stay, with half of the CCTA group being discharged within 8.6 hours but only 10% of the control group being released so quickly. The amount of time until a diagnosis of heart disease either ruled out or confirmed was also shorter for the CCTA group than for the controls, and more patients receiving CCTA were discharged directly from the ED rather than being admitted to an observation unit. The percentage of patients actually diagnosed with heart disease was similar in both groups at approximately 8%, and there were no missed diagnoses in either group.

Analysis of total clinical resources used from arrival to discharge indicated that CCTA participants had more diagnostic procedures than control group members did, but the difference was not statistically significant. Neither were there any significant disparities between groups in total costs through the 28-day follow-up in those participants for whom cost information was available. CCTA group participants were exposed to higher cumulative doses of radiation; however, the investigators noted that recent studies have indicated that CCTA can frequently be effectively performed using lower doses and suggest that future studies assess the usefulness of low-dose CCTA examination.

“It’s very important to strive for the greatest efficiency in diagnostic testing, and in this study, additional testing was primarily carried out in patients found to have coronary artery disease,” Hoffmann noted. “There also were fewer adverse clinical events in those receiving CCTA, although the study group was too small to conclude that CCTA reduced those risks. Showing at a variety of clinical sites that CCTA is at least as good as standard ED evaluation without increasing costs elevates the procedure from one appropriate only for specialized settings to one that can be applied in many centers. I’d really like to commend the commitment and teamwork of all the participating sites and departments, which was essential to the successful completion of this study.” Dr. Hoffmann is an associate professor of radiology at Harvard Medical School (Boston, MA, USA).

Related Links:

Massachusetts General Hospital




Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Bipolar Coagulation Generator
Aesculap
Digital Color Doppler Ultrasound System
MS22Plus
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.